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Chemical modulation of mutant mGlu 1 receptors derived from deleterious GRM1 mutations found in schizophrenics 
Experimental
All commercial chemicals and solvents were reagent grade and were used without further purification unless otherwise specified. All reactions were carried out employing standard chemical techniques under inert atmosphere. Analytical thin layer chromatography was performed on 250 µm silica gel plates from Sorbent Technologies was employed routinely to follow the course of reactions. NMR spectra were recorded on a 400 MHz Bruker AV-400, 500 MHz Bruker DRX-500 and 600 MHz AV-II instruments. 1 H chemical shifts are reported as δ values in ppm relative to the residual solvent peak (DMSO-d 6 = 2.50, CDCl 3 = 7.26). Data are reported as follows: chemical shift, integration, multiplicity (s= singlet, d= doublet, dd= double of doublet, t= triplet, q = quartet, m= multiplet) and coupling constant (Hz). 13 C chemical shifts are reported as δ values in ppm relative to the residual solvent peak (DMSO-d 6 = 39.52, CDCl 3 = 77.16). Analytical HPLC was performed on an Agilent 1200 LCMS with UV detection at 214 nm and 254 nm along with ELSD detection. The purity of all tested compounds was greater than 98% based on analytical HPLC. Preparative purification of library compounds was performed on a Gilson 215 preparative LC system. Low resolution mass spectra were obtained on an Agilent 1200 LCMS with electrospray ionization. High resolution mass spectra were recorded on a Waters QToF-API-US plus Acquity system with electrospray ionization. 8, 163.6, 146.0, 145.4, 141.4, 140.0, 136.5, 134.4, 133.7, 131.9, 130.7, 126.4, 124.6, 123.9, 120.7, 118.3, 20. 7, 160.7, 145.8, 144.5, 141.1, 139.5, 134.4, 133.8, 132.9, 131.8, 130.8, 127.2, 125.0, 123.9, 120.8, 118.4 7, 158.3, 139.6, 138.7, 138.1, 134.5, 133.9, 131.8, 131.0, 130.7, 129.4, 126.7, 124.0, 121.3, 119.1, 118.8 General synthesis of N-(2-chloro-4-nitrophenyl)picolinamides. In a microwave vial, 2.20 mmol (1.0 equivalents) of the 3-substituted pycolinic acid were added and dissolved in 5 mL of DCE:DIEA (9:1), then 1254 mg (3.30 mmol, 1.5 equivalents) of HATU were added. The mixture was stirred for five minutes, and 2.64 mmol (1.2 equivalents) of 3-S4 chloro-4-nitroaniline dissolved in 5 mL of DCE:DIEA (9:1) were added, followed by 3 drops of DMF. The reaction was heated in the microwave at 120 °C for 30 minutes. The reaction was cooled to room temperature and water was added, causing the precipitation of the product. The crude was filtrated in vacuo and carefully triturated with cold methanol. 141.1, 134.9, 127.7, 127.0, 126.8, 121.7, 119.0, 19.8 . 149.7, 147.8, 143.7, 142.5, 139.6, 129.4, 128.0, 127.6, 127.1, 121.5, 118.9 . 151.6, 147.6, 141.8, 139.0, 128.8, 126.7, 121.0, 120.4, 116.9, 115.7 .
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N-(3-chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylpicolinamide (19k
N-(3-chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-chloropicolinamide (19l
N-(3-chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-hydroxypicolinamide (19o
N-(2-chloro-4-nitrophenyl)-3-methylpicolinamide (20a
N-(2-chloro-4-nitrophenyl)-3-chloropicolinamide (20b
N-(4-amino-2-chlorophenyl)-3-methylpicolinamide (21a
General synthesis of substituted
N-(3-chloro-4-(1,3-dioxoisoindolin-2-
yl)phenyl)picolinamides. In a microwave vial, 0.0709 mmol (1.0 equivalents) of the 3substituted N-(4-amino-2-chlorophenyl)picolinamide and 0.106 mmol (15 equivalents) of the substituted phthalic anhydride were added and dissolved in 1 mL of NMP. The vial was sealed and the mixture was heated at 200 °C for 20 minutes. After this time, the reaction was quenched with the addition of water, and was worked up by extraction with DCM (2 mL, thrice). The organic phased was filtered through a phase separator, volatiles were evaporated; the crude was dissolved in DMSO and purified by preparative HPLC. 166.8, 163.1, 145.9, 144.7, 141.9, 139.9, 138.6, 136.7, 136.6, 133.9, 133.7, 132.3, 130.8, 128.6, 126.4, 124.9, 121.5, 120.8, 118.4, 20.6, 17.7 N-(3-chloro-4-(5-methyl-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylpicolinamide (23b) . 166.9, 163.2, 145.9, 145.8, 144.8, 141.8, 139.9, 136.6, 134.9, 133.7, 132.2, 130.8, 129.3, 126.4, 124.8, 124.4, 123.8, 120.8, 118.4, 22.0, 20.6 N-(3-chloro-4-(4-chloro-1,3-dioxoisoindolin-2-yl) N-(3-chloro-4-(5-chloro-1,3-dioxoisoindolin-2-yl) N-(3-chloro-4-(4-fluoro-1,3-dioxoisoindolin-2-yl) N-(3-chloro-4-(5-fluoro-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylpicolinamide (23f) . 165.7, 165.4, 163.2, 145.8, 144.8, 141.9, 140.1, 136.6, 134.7 ( 3 N-(3-chloro-4-(4-methyl-1,3-dioxoisoindolin-2-yl) 166.8, 160.7, 145.8, 144.6, 141.1, 139.4, 138.7, S8 136.7, 133.9, 133.8, 132.9, 132.3, 130.9, 128.6, 127.1, 125.2, 121.5, 120.8, 118.3, 17. N-(3-chloro-4-(5-methyl-1,3-dioxoisoindolin-2-yl)phenyl)-3-chloropicolinamide (24b) . 166.8, 160.7, 145.8, 145.8, 144.6, 141.1, 139.5, 135.0, 133.8, 132.9, 132.2, 130.9, 129.2, 127.1, 125.2, 124.4, 123.8, 120.8, 118.3, 22. N-(3-chloro-4-(4-chloro-1,3-dioxoisoindolin-2-yl) 160.7, 145.8, 144.5, 141.1, 139.7, 136.1, 135.3, 133.9, 133.7, 132.9, 132.0, 130.8, 127.6, 127.2, 124.7, 122.4, 120.8, 118.4 N-(3-chloro-4-(5-chloro-1,3-dioxoisoindolin-2-yl) 8, 170.4, 168.7, 155.3, 152.5, 145.8, 145.1, 144.2, 140.0, 138.5, 137.5, 136.8, 135.1, 133.9, 132.1, 130.7, 129.7, 129.1, 125.3, 124.3 N-(3-chloro-4-(4-fluoro-1,3-dioxoisoindolin-2-yl) 5, 163.3, 160.7, 157.9 (d, 1 J CF =267 Hz), 145.8, 144.5, 141.1, 139.7, 136.96 (d, 3 J CF =7.6 Hz), 133.9, 133.8, 132.9, 130.8, 127.2, 127.0, 124.6, 122.8 ( 2 J CF =19.7 Hz), 121.7, 120.8, 120.1, 118.4 N-(3-chloro-4-(5-fluoro-1,3-dioxoisoindolin-2-yl) 165.7, 165.4, 160.8, 145.9, 144.6, 141.2, 139.8, 134.7 ( 3 
N-(3-chloro-4-(4-methyl-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylpicolinamide (23a
SUPPLEMENTAL FIGURES
Supplemental Figure 1. Treatment with mGlu 1 negative allosteric modulators noncompetitively inhibits glutamate-mediated Ca signaling in representative Sz mutants.
The stable cells expressing the mGlu 1 WT and Sz mutant receptors (K563N and A683E) were pretreated with 1 µM of the potent mGlu 1 NAM 7 for 2.2 min, and immediately stimulated with glutamate (A) or DHPG (B). In all cases, non-competitive antagonism (decrease in the Glu max) is apparent, highlighting that the Sz mutant receptors can be modulated by a prototypical mGu 1 NAM. S11 Supplemental Figure 2. Effect of an mGlu 1 NAM (7) or PAM (24c) on amphetamineinduced hyperlocomotion (AHL). In agreement with early literature reports, mGlu 1 NAMs potently reverse AHL, however, mGlu 1 PAMs had never been studied in this paradigm. Here, mGlu 1 PAM 24c has no effect or may slightly potentiate the effect of amphetamine in WT rats, possessing native mGlu 1 receptors. 5 and 23c behaved similarly (data not shown). N = 6/group. At 100 mg/kg dose of 24c, brain:plasma ratio (K p ) of 0.84 (at t = 1.25 hours), 100 mg/kg 23c, brain:plasma ratio (K p ) of 0.69 (at t = 1.25 hours), 100 mg/kg 5, brain:plasma ratio (K p ) of 0.19 (at t = 1.25 hours). 
